高级别胶质瘤患者中O6-甲基鸟嘌呤甲基转移酶启动子甲基化的意义:最佳截断点、CpG位点及基因检测方法
这项回顾性观察研究纳入95例接受全切及放化疗的高级别胶质瘤患者,用二代测序评估MGMT启动子CpG岛甲基化状态,按10%截断点分为未甲基化、低甲基化和高甲基化,发现MGMT启动子甲基化是总生存和无进展生存的强预测因子,CpG 79-83和CpG 84-87高甲基化与更好生存结局相关(p<0.05)。
要点
- MGMT启动子甲基化是高级别胶质瘤总生存和无进展生存的强预测因子。
- CpG 79-83和CpG 84-87高甲基化与更好生存结局相关(p<0.05)。
- 全启动子CpG岛测序显示特定位点甲基化可能更精确预测临床结局。
核心结论
- 本研究结果支持MGMT启动子甲基化在高级别胶质瘤患者中的预后价值。
- 全启动子CpG岛测序表明,特定CpG位点的甲基化可能更精确地预测临床结局。
研究设计与样本
- 回顾性观察研究,连续纳入接受手术全切后同步放化疗及辅助化疗的高级别胶质瘤患者。
- 共纳入95例患者,平均年龄51.50 ± 12.36岁。
- 对切除肿瘤组织的MGMT启动子CpG岛甲基化状态采用二代测序检测。
- 结局按CpG 70-78、CpG 79-83、CpG 84-87、CpG 70-87及全启动子分组。
- 定量分析以10%为截断点二分为甲基化或未甲基化,并进一步分级为<10%未甲基化、10%-30%低甲基化和30%-100%高甲基化。
主要发现
- 总生存(OS)为14.53 ± 1.92个月(95% CI 10.77-18.30),无进展生存(PFS)为10.90 ± 2.05个月(95% CI 6.89-14.92)。
- MGMT启动子在38.2%的病例中甲基化,在10.5%的病例中高甲基化。
- MGMT启动子甲基化状态被认为是OS和PFS的非常强预测因子。
- CpG 79-83和CpG 84-87岛高甲基化与更好生存结局强烈相关(p < 0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate O6-methyl guanine methyltransferase (MGMT) promoter methylation status in high grade glioma patients and to identify the best cutoff point as well as the most predictive CpG loci for patients survival. METHOD: Consecutive high grade glioma patients treated with surgical gross total resection followed by concomitant radiochemotherapy and adjuvant chemotherapy were included in this retrospective observational study. Methylation status of MGMT promoter CpG island of resected tumor tissue were evaluated using next generation sequencing assay. The outcomes were grouped as CpG 70-78, CpG 79-83, CpG 84-87, CpG 70-87, and whole promoter. Quantitative analyses were dichotomized as methylated or unmethylated based on the cutoff points set to %10, and methylation was further graded as <%10 unmethylated, %10-30 low-methylated, and %30-100 high-methylated. RESULTS: Total of 95 patients with the mean age of 51.50 ± 12.36 years were included in the study. Overall survival (OS) and progression free survival (PFS) were 14.53 ± 1.92 (95% CI 10.77-18.30) and 10.90 ± 2.05 (95% CI 6.89-14.92) months, respectively. MGMT promoter was methylated in 38.2% of cases and high-methylated in 10.5% of cases. Methylation status of MGMT promoter was recognized as a very powerful predictor of OS and PFS. In particular, high-methylation of CpG 79-83 and CpG 84-87 islands at promoter region were strongly associated with better survival outcomes (p < 0.05). CONCLUSION: Our outcomes support the prognostic value of MGMT promoter methylation in patients with high grade glioma. Sequencing of whole promoter CpG islands demonstrated that methylation of particular CpG sites might predict clinical outcomes more precisely.
引用
- Buyuktepe M, Kaplan I, Bayatli E, et al. Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay. J Neurooncol. 2023. PMID: 37474746. doi:10.1007/s11060-023-04397-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。